Expression level of wild-type survivin in gastric cancer is an independent predictor of survival

Figure 1 Amplification, separation and visualization of survivin (185 bp), survivin-2B (214 bp) survivin-△Ex3 (184 bp), and G6PDH (256 bp) mRNA (40 cycles) in a typical case.

Figure 2 A: RT-PCR amplification of G6PDH in paired samples of normal gastric mucosa and gastric carcinoma. B: Relative (G6PDH-normalised) mRNA levels of survivin variants in paired samples of normal gastric mucosa and gastric carcinoma. Two-tailed P values were calculated by the Mann-Whitney U test.

Figure 3 Relative mRNA levels of survivin variants. A: Significant decrease of relative (G6PDH-normalised) mRNA levels of survivin-2B in advanced stages (P = 0.001, Mann-Whitney U test). B: Significant decrease of relative (G6PDH-normalised) mRNA levels of survivin-2B in undifferentiated type (P = 0.004, Mann-Whitney U test). C: Significantly lower ratio of survivin-2B/survivin in advanced stages than that in early stages (P = 0.018, Mann-Whitney U test).

Figure 4 Histochemical staining for Ki-67 and apoptotic tumor cells. A: TUNEL in situ labeling for detecting apoptotic cells and bodies (arrows, magnification × 400) in adenocarcinoma. B: Ki-67 nuclear immunohistochemical staining revealing proliferating tumor cells in adenocarcinoma (magnification × 400).

Figure 5 postoperative survivals of 79 gastric carcinoma patients. A: Shorter survival time of patients with high expression of wild-type survivin mRNA compared to patients with low expression of wild-type survivin expression (P = 0.003, log-rank test).B: No significance in expression of survivin-2B mRNA (P = 0.166, log-rank test). C: No significance in expression of survivin-△Ex3 mRNA (P = 0.441, log-rank test).